A randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR).

Trial Profile

A randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR).

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Mitoxantrone (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Cyclophosphamide; Fludarabine; Fludarabine; Lenograstim
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms ARCTIC
  • Most Recent Events

    • 20 Oct 2012 Accrual to date is 97% according to United Kingdom Clinical Research Network record.
    • 21 Sep 2012 Accrual to date is 95% according to United Kingdom Clinical Research Network record.
    • 06 Sep 2012 Accrual to date is 93% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top